drugset
drugset / Trial / NCT05032560

Safety and Pharmacokinetics Study in Healthy Japanese Volunteers

NCT05032560 ↗

Phase 1 Completed 48 enrolled Abivax S.A.
RandomizedSequentialQuadruple-blindTreatment

Summary

The study consists of Part A, a randomized double-blind, single-ascending-dose study, and Part B, a randomized, double-blind, semi-sequential, escalating multiple-dose study, in healthy Japanese volunteers.

Timeline

Start
2021-09-27
Primary completion
2022-02-18
Completion
2022-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Obefazimod Small molecule 25 mg Oral
Subject Obefazimod Small molecule 50 mg Oral

Indications

No indication recorded.